The Economic Times

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka

India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging among millions needing obesity management. Broader specialist adoption and a growing prescriber base are fueling this expansion, promising substantial market growth.